SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is drawing significant attention as its community debates its immediate future, with some anticipating major "altseason" gains fueled by ongoing technical breakouts and rumors of potential new exchange listings. Proponents emphasize its core utility as fast, low-fee digital money and the transformative potential of upcoming protocol upgrades like LitVM. However, a strong contingent remains highly skeptical, labeling it a "dead coin" amid broader crypto market volatility.

Polygon

Polygon is experiencing a surge in conversation fueled by strong market momentum and its ongoing Open Money Stack Initiative, alongside reports of significant on-chain revenue growth and strategic token burning. The community is actively discussing Polygon's perceived undervaluation and its pivotal role as a scalable Layer 2 solution for Ethereum, anticipating its potential to dominate the payments sector amidst growing institutional interest and debates around its token's branding.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi ($FIS) is actively trending due to widespread community excitement, primarily driven by persistent rumors of new major exchange listings like Coinbase, coupled with noticeable increases in trading volume. The community is bullish, emphasizing its core utility as a liquid staking protocol with AI-integrated and cross-chain bridging technology, seeing it as an undervalued asset poised for significant "altseason" gains within the multi-chain crypto landscape.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending amidst strong community sentiment, driven by its innovative "Airlock" mechanism where over 35% of the token supply has been voluntarily locked. This community-driven supply control fosters a "Make Holding Great Again" narrative, aiming for broad exchange listings and is further buoyed by recent celebrity engagement. The highly bullish community actively champions AIRCOIN as a revolutionary and undervalued project within the crypto space.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

The biotech sector, reflected in LABU's performance, continues to capture market attention amid accelerating advancements in AI-driven drug discovery and expectations of accommodative monetary policy. The community is actively debating the sustainability of this strong upward trend, with many anticipating further sector growth and a rotation of capital into biotech innovation. Discussions highlight the transformative impact of artificial intelligence on pharmaceutical research and development, contrasting the sector's momentum against broader market concerns.

What is Mars Protocol?  Mars Protocol consists of a money market, called Red Bank, and a generalized credit primitive called Rover. Mars Protocol utilizes a so-called hub and outpost topology, whereby its base, Mars Hub acts as a command center for numerous outposts. Each outpost consists of an instance of Red Bank and Rover and the first of many outposts will be the Osmosis chain.

Mars

MARS CRYPTO is trending due to community excitement surrounding a nascent meme token, with users speculating on its potential for rapid growth and drawing parallels to other popular meme coins. While some discussion also involves an upcoming space technology ETF sharing the $MARS ticker, the current speculative interest largely centers on the cryptocurrency.

Constellation Software Inc

Constellation Software is trending as investors assess its robust Q3 results, which reported strong revenue and free cash flow growth amidst a significant share price pullback. The community is actively debating whether this represents a rare buying opportunity due to perceived undervaluation and solid fundamentals, while also considering potential impacts from AI on its niche software empire. Analysts largely maintain bullish outlooks, highlighting the company's proven acquisition strategy and stable leadership.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is drawing significant community attention, catalyzed by surging trading volume and substantial token burns from major exchanges. Discussions are vibrant around potential new exchange listings and ongoing ecosystem developments like LUNCVERSE, leading many to view LUNC as an undervalued asset poised for a major resurgence within the evolving altcoin landscape.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense community debate as its underlying biotech index (XBI) continues a robust and sustained rally, defying expectations for a significant pullback. Many investors express frustration over XBI's persistent upward momentum, viewing it as an overextended 'pump' or a 'hideout' for market makers, while others anticipate further gains driven by sector rotation and buyout activity, creating a highly polarized outlook for this bear-leveraged ETF.

Willow Lane Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 3, 2024 and is headquartered in New York, NY.

Willow Lane Acquisition Corp. - Ordinary Shares - Class A

Willow Lane Acquisition Corp. is trending as the community anticipates its merger with Boost Run, an AI infrastructure company widely considered an undervalued "sleeping giant" in a high-demand sector. Investors are actively discussing the imminent S-4 filing as the next catalyst, drawing comparisons to successful AI infrastructure plays and expecting a significant run in the burgeoning data center market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Healthcare Stocks To Watch Now - January 9th

UnitedHealth Group, Hims & Hers Health, and Johnson & Johnson are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly...

<ul class="summary-bullets"><li>Dudum said individuals are taking greater control of care through DTC access, preventive health, and wider use of AI.</li><li>BofA and Citi cut targets, citing margin pressure and a heavy investment outlook for 2026.</li><li>Novo’s broader rollout of oral Wegovy intensified competition in the GLP-1 market.</li></ul><p>Hims &amp; Hers Health CEO Andrew Dudum said the company is leaning into a consumer-led healthcare model in 2026, even as Wall Street grows more cautious about margins and near-term earnings pressure.</p><h2 class="st-heading-2"><strong>Dudum Sees AI As Key Focus</strong></h2><p>In a blog post on Thursday, Dudum said healthcare is moving toward personalized models that give individuals greater control over their care. He pointed to the growing role of direct-to-consumer channels, a rising emphasis on preventive and longevity-focused care, and broader use of AI to improve access and personalization.</p><p>He said there is a growing demand for easier access, lower prices and more personalized care, as well as heightened interest in early testing, diagnostics and continuous health tracking. Dudum added that AI is also being used to minimize friction in care delivery and enable more reliable engagement between consumers and providers.</p><h2 class="st-heading-2"><strong>OpenAI Pushes Into Healthcare</strong></h2><p>The development comes as large technology platforms increase their presence in healthcare.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/open-ai-launches-chatgpt-health/cmxzOpYR42A">OpenAI on Wednesday launched ChatGPT Health</a>, which helps users blend health information with AI-driven insights.</p><p>OpenAI said users can connect their electronic health records and fitness apps, such as Apple Health, Function and MyFitnessPal, securely to have ChatGPT help them make sense of test results and guide their health regimens in light of personal trends. The company said ChatGPT Health was developed over two years in collaboration with more than 260 physicians.</p><h2 class="st-heading-2"><strong>Wall Street Turns Cautious</strong></h2><p>On Thursday, Bank of America Securities (BofA) lowered its price target on Hims &amp; Hers to $29 from $32 and maintained an 'Underperform' rating, saying expectations for 2026 appear too optimistic.</p><p>The firm said consensus forecasts for sales and earnings before interest, taxes, depreciation, and amortization (EBITDA) margins are elevated, describing 2026 as a “big investment year” for the company. BofA added that it sees downside risk to 2026 revenue and margins, with negative earnings revisions likely in the coming months.</p><p><a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-enters-2026-on-solid-ground-stock-rises-even-after-novo-nordisk-leaves-it-off-wegovy-partner-list/cmxw0eER4Rq">Citigroup also maintained a ‘Sell’ rating&nbsp;</a>with a $30 price target, pointing to competitive pressures following a move by Novo Nordisk, which said its oral Wegovy pill is now broadly available in the U.S., with prices starting at $149 a month for certain doses and as low as $25 for some commercially insured patients.</p><p>Citi noted that Hims was again excluded from Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx, likely reflecting disagreements around Hims’ compounded semaglutide strategy. The firm added that broader access to oral Wegovy could weigh on Hims’ GLP-1 offering this year.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Hims was ‘bullish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_aa9782247d.webp" alt="hims ss.png" width="975" height="144"><figcaption>HIMS sentiment and message volume as of January 9| Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 32% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Hims & Hers CEO Bets On Personalized Healthcare And AI In 2026 — Wall Street Braces For A Costly Year

The development follows OpenAI’s rollout of ChatGPT Health, which helps users blend health information with AI-driven insights.

Equity

Healthcare Stocks To Keep An Eye On - January 8th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Aclarion, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. As it...

Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?

HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.

Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts

Hims & Hers Health, Inc. (HIMS) reached $35.45 at the closing of the latest trading day, reflecting a +2.12% change compared to its last close.

Best Healthcare Stocks To Follow Today - January 6th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, Tempus AI, Novartis, and Hims & Hers Health are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul><p>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.</p><p>The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.</p><h2 class="st-heading-2"><strong>Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</strong></h2><p>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.</p><p>Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.</p><h2 class="st-heading-2"><strong>Broader Growth Drivers Remain in Focus</strong></h2><p>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.</p><p>Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;</p><p>Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.</p><p>In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.</p><h2 class="st-heading-2"><strong>Investors Look Beyond Near-Term GLP-1 Pressure</strong></h2><p>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.</p><p>Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure><p>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”</p><p><stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl></p><p>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.</p><p><stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl></p><p><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Best Healthcare Stocks To Consider - January 5th

UnitedHealth Group, Johnson & Johnson, Hims & Hers Health, McKesson, Intuitive Surgical, HCA Healthcare, and Tempus AI are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization

HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.

Promising Healthcare Stocks To Keep An Eye On - January 4th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, Hims & Hers Health, Ironwood Pharmaceuticals, and Tempus AI are the seven Healthcare stocks to watch today, according to...

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

Hims & Hers Health Inc

Traders are heavily discussing intensified competition in the GLP-1 weight-loss market, especially after Amazon Pharmacy began offering Novo Nordisk's Wegovy for as low as $25/month.

Amidst a significant stock decline, many traders are eyeing the $25-$28 price range as a critical support level and a potential generational buying opportunity.

Concerns are rising about the company's lack of a sustainable competitive advantage and increasing regulatory pressure in the evolving telehealth and wellness sector.

User sentiment is critical of CEO Andrew Dudum, with many questioning his communication and leadership during the significant stock decline and increased market challenges.

Many traders believe the sharp recent price decline is a strategic institutional move to trigger stop losses and accumulate shares from retail investors at lower prices.

Current Price	$31.72
Prev Close	$33.87
Open	$34.31
Dividend Yield	0.00%
50-Day Moving Average	$37.50
Beta	2.11
Avg. Volume	12.42M
PE Ratio	58.59

52-Week High	$72.98
52-Week Low	$23.97
Market Capitalization	$7.71B
EPS (Annual)	$0.5322
Price to Book	12.41
Revenue Per Employee	$901,963.35
Enterprise Value/EBITDA	N/A

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMSHims & Hers Health Inc